Menopause supplements costing more than £400 a year ‘no better than cheap multivitamin’
There is no persuasive evidence that menopause supplements have a significant effect on women’s symptoms, some of them are dangerous, and the pricing and marketing is exploitative and confusing. They are a massive rip-off for consumers who desperately want to be well.”Martin Last, the director general of the Health Food Manufacturers’ Association, said: “We encourage industry manufacturers to formulate and recommend supplements as required by the many food regulations that apply to food supplements. Many life stages, including the menopause, may create increased nutritional demands on an individual and these may be met by supplementation as an addition to a healthy diet.”Explore more on these topicsMenopauseWomenHealthWomen's healthNutrition (Life and style)Nutrition (Science)newsShareReuse this content
- ▪There is no persuasive evidence that menopause supplements have a significant effect on women’s symptoms, some of them are dangerous, and the pricing and marketing is exploitative and confusing.
- ▪They are a massive rip-off for consumers who desperately want to be well.”Martin Last, the director general of the Health Food Manufacturers’ Association, said: “We encourage industry manufacturers to formulate and recommend supplements as
- ▪Many life stages, including the menopause, may create increased nutritional demands on an individual and these may be met by supplementation as an addition to a healthy diet.”Explore more on these topicsMenopauseWomenHealthWomen's healthNut
The Guardian — World publishes from United Kingdom and files mainly under world. We currently carry 4,297 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | World news | The Guardian |
| Canonical URL | https://www.theguardian.com/society/2026/sep/30/menopause-supplements-no-better-than-multivitamin-which |
| Publication time | Wed, 30 Sep 2026 06:00:11 GMT |
| Retrieval time | 2026-09-30T06:11:55.929Z |
| Last seen | 2026-09-30T06:11:55.929Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | eG_gK3nV8Ab6 · 1 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
The global menopause supplement market is valued at nearly $17bn and is expected to reach $25bn by 2030 Photograph: kali9/Getty ImagesView image in fullscreenThe global menopause supplement market is valued at nearly $17bn and is expected to reach $25bn by 2030 Photograph: kali9/Getty ImagesMenopauseMenopause supplements costing more than £400 a year ‘no better than cheap multivitamin’Many products aimed at women over 45 lack meaningful quantities of key nutrients, consumer watchdog Which? foundAnna Bawden Health and social affairs correspondentWed 30 Sep 2026 02.00 EDTSharePrefer the Guardian on GoogleMenopause supplements costing more than £400 a year are no better than a £22-a-year multivitamin, according to analysis by the consumer watchdog Which?.Which? found that many popular…
Excerpt limited to ~120 words for fair-use compliance. The full article is at World news | The Guardian.
Discussion
0 commentsMore from World news | The Guardian
